Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020.
Centers for Disease Control and Prevention, U.S.
Health Personnel
Hepacivirus
/ genetics
Hepatitis C
/ prevention & control
Humans
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Occupational Exposure
Post-Exposure Prophylaxis
Practice Guidelines as Topic
RNA, Viral
/ analysis
United States
United States Public Health Service
Journal
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
ISSN: 1545-8601
Titre abrégé: MMWR Recomm Rep
Pays: United States
ID NLM: 101124922
Informations de publication
Date de publication:
24 07 2020
24 07 2020
Historique:
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Exposure to hepatitis viruses is a recognized occupational risk for health care personnel (HCP). This report establishes new CDC guidance that includes recommendations for a testing algorithm and clinical management for HCP with potential occupational exposure to hepatitis C virus (HCV). Baseline testing of the source patient and HCP should be performed as soon as possible (preferably within 48 hours) after the exposure. A source patient refers to any person receiving health care services whose blood or other potentially infectious material is the source of the HCP's exposure. Two options are recommended for testing the source patient. The first option is to test the source patient with a nucleic acid test (NAT) for HCV RNA. This option is preferred, particularly if the source patient is known or suspected to have recent behaviors that increase risk for HCV acquisition (e.g., injection drug use within the previous 4 months) or if risk cannot be reliably assessed. The second option is to test the source patient for antibodies to hepatitis C virus (anti-HCV), then if positive, test for HCV RNA. For HCP, baseline testing for anti-HCV with reflex to a NAT for HCV RNA if positive should be conducted as soon as possible (preferably within 48 hours) after the exposure and may be simultaneous with source-patient testing. If follow-up testing is recommended based on the source patient's status (e.g., HCV RNA positive or anti-HCV positive with unavailable HCV RNA or if the HCV infection status is unknown), HCP should be tested with a NAT for HCV RNA at 3-6 weeks postexposure. If HCV RNA is negative at 3-6 weeks postexposure, a final test for anti-HCV at 4-6 months postexposure is recommended. A source patient or HCP found to be positive for HCV RNA should be referred to care. Postexposure prophylaxis of hepatitis C is not recommended for HCP who have occupational exposure to blood and other body fluids. This guidance was developed based on expert opinion (CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recommend Rep 2001;50[No. RR-11]; Supplementary Figure, https://stacks.cdc.gov/view/cdc/90288) and reflects updated guidance from professional organizations that recommend treatment for acute HCV infection. Health care providers can use this guidance to update their procedures for postexposure testing and clinical management of HCP potentially exposed to hepatitis C virus.
Identifiants
pubmed: 32701942
doi: 10.15585/mmwr.rr6906a1
pmc: PMC8631757
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Références
J Infect Dis. 2007 Nov 15;196(10):1474-82
pubmed: 18008226
Hepatology. 2002 Oct;36(4 Pt 1):993-1000
pubmed: 12297849
Hepatology. 1999 Mar;29(3):908-14
pubmed: 10051497
J Clin Virol. 2017 Apr;89:1-4
pubmed: 28171829
MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):362-5
pubmed: 23657112
Transfusion. 2002 Aug;42(8):1037-45
pubmed: 12385416
Clin Infect Dis. 2005 Nov 15;41(10):1423-30
pubmed: 16231252
J Viral Hepat. 2008 Feb;15(2):120-8
pubmed: 18184195
J Clin Gastroenterol. 2015 Apr;49(4):e31-40
pubmed: 24457946
Transfusion. 2009 Nov;49(11):2454-89
pubmed: 19682345
AIDS. 2009 Jan 2;23(1):89-93
pubmed: 19050390
Clin Infect Dis. 2013 Feb;56(3):405-13
pubmed: 23090930
MMWR Recomm Rep. 2001 Jun 29;50(RR-11):1-52
pubmed: 11442229
Lancet Infect Dis. 2017 Feb;17(2):215-222
pubmed: 28029529
J Hosp Infect. 2017 Jun;96(2):195-198
pubmed: 28314636
Transfusion. 2000 Feb;40(2):143-59
pubmed: 10685998
J Infect Dis. 2010 May 1;201(9):1381-9
pubmed: 20353362
Clin Infect Dis. 2014 Dec 15;59(12):1678-85
pubmed: 25186590
J Virol. 2005 May;79(10):6023-34
pubmed: 15857988
MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19
pubmed: 24352112
Infect Control Hosp Epidemiol. 2009 Mar;30(3):299-300
pubmed: 19199826
Curr Opin Infect Dis. 2016 Aug;29(4):373-80
pubmed: 27306563
J Infect Dis. 2015 Nov 1;212(9):1407-19
pubmed: 25883387
Clin Infect Dis. 2019 Jul 18;69(3):514-522
pubmed: 31220220
J Viral Hepat. 2006 Jan;13(1):34-41
pubmed: 16364080
J Exp Med. 2001 Nov 19;194(10):1395-406
pubmed: 11714747
J Lab Physicians. 2017 Jan-Mar;9(1):20-25
pubmed: 28042212
J Med Virol. 2014 Oct;86(10):1722-9
pubmed: 25042465
Lancet Gastroenterol Hepatol. 2019 Apr;4(4):269-277
pubmed: 30660617
MMWR Morb Mortal Wkly Rep. 2019 Jan 25;68(3):61-66
pubmed: 30677008
Am J Infect Control. 2017 Sep 1;45(9):1001-1005
pubmed: 28449917
Clin Infect Dis. 2017 Jan 1;64(1):92-99
pubmed: 27682067
Clin Gastroenterol Hepatol. 2020 Feb;18(2):511-513
pubmed: 31009792
JAMA. 2002 Sep 25;288(12):1469; author reply 1469-71
pubmed: 12243628
Transfusion. 2005 Jun;45(6):994-1002
pubmed: 15934999
J Hepatol. 2009 Apr;50(4):693-704
pubmed: 19231006
Lancet Gastroenterol Hepatol. 2017 May;2(5):347-353
pubmed: 28397698
Infect Control Hosp Epidemiol. 2010 Mar;31(3):203-32
pubmed: 20088696
Eur J Gastroenterol Hepatol. 2011 Jun;23(6):515-20
pubmed: 21537126